Kagen Alexander, Fowler Kathryn, Sirlin Claude B
Beth Israel Medical Center, Department of Radiology, 2nd Floor, First Avenue at 16th Street, New York, NY 11231, USA.
Washington University School of Medicine, 510 S. Kings Highway Boulevard, St Louis, MO 63110, USA.
Hepat Oncol. 2014 Jan;1(1):95-105. doi: 10.2217/hep.13.11. Epub 2013 Dec 20.
The current algorithm for the imaging diagnosis of hepatocellular carcinoma accurately detects large, progressed tumors displaying the classical imaging features of arterial hyperenhancement with 'washout' and/or 'capsule' appearance. Liver MRI with the relatively newer hepatobiliary agent, gadoxetate disodium, provides information on hepatocellular function in addition to vascularity, facilitates detection of small progressed tumors, as well as early/vaguely nodular tumors, and shows promise for characterizing hepatocellular carcinoma biology. Prediction of tumor grade, presence of biliary and stem cell markers, microvascular invasion, future hypervascularization and post-treatment recurrence have all been studied with gadoxetate disodium-enhanced MRI with encouraging results. Incorporation of gadoxetate disodium-enhanced MRI into standard diagnostic and management algorithms will likely unfold in the future.
目前肝细胞癌的成像诊断算法能够准确检测出具有动脉期强化伴“廓清”和/或“包膜”表现等典型成像特征的大型进展期肿瘤。使用相对较新的肝胆对比剂钆塞酸二钠进行肝脏磁共振成像(MRI),除了提供血管信息外,还能提供肝细胞功能信息,有助于检测小型进展期肿瘤以及早期/微小结节状肿瘤,并有望对肝细胞癌生物学特性进行表征。使用钆塞酸二钠增强MRI对肿瘤分级、胆管和干细胞标志物的存在、微血管侵犯、未来的血管增多以及治疗后复发情况进行预测的研究均取得了令人鼓舞的结果。将钆塞酸二钠增强MRI纳入标准诊断和管理算法很可能会在未来实现。